Recent discussions on X about Astera Labs (ALAB) have been buzzing with excitement over the company’s latest quarterly earnings, particularly the reported 150% year-on-year revenue growth and strong cash flow margins. Many users are pointing to the firm’s robust financials as a sign of its critical role in the AI infrastructure space, with some expressing awe at the scale of its operational success. The conversation often highlights the company’s ability to exceed expectations, fueling intense interest in its future trajectory.
Additionally, there’s notable chatter around specific product lines like Scorpio X, which are reportedly gaining traction among AI and cloud providers, further driving enthusiasm. Some posts also mention insider activity, such as planned securities sales by company directors, sparking curiosity about potential implications. The dialogue on X reflects a dynamic mix of optimism and scrutiny as investors and analysts dissect these developments.
Note: This discussion summary was generated from an AI condensation of post data.
Astera Labs Congressional Stock Trading
Members of Congress have traded $ALAB stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ALAB stock by members of Congress over the last 6 months:
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $15,000 on 02/27.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Astera Labs Insider Trading Activity
Astera Labs insiders have traded $ALAB stock on the open market 210 times in the past 6 months. Of those trades, 0 have been purchases and 210 have been sales.
Here’s a breakdown of recent trading of $ALAB stock by insiders over the last 6 months:
- SANJAY GAJENDRA (President and COO) has made 0 purchases and 39 sales selling 1,122,778 shares for an estimated $133,198,080.
- JITENDRA MOHAN (Chief Executive Officer) has made 0 purchases and 83 sales selling 1,082,778 shares for an estimated $119,527,107.
- MICHAEL TRUETT TATE (Chief Financial Officer) has made 0 purchases and 19 sales selling 727,968 shares for an estimated $85,657,580.
- MANUEL ALBA has made 0 purchases and 48 sales selling 228,000 shares for an estimated $18,148,006.
- STEFAN A DYCKERHOFF has made 0 purchases and 8 sales selling 52,000 shares for an estimated $9,065,696.
- PHILIP MAZZARA (General Counsel and Secretary) has made 0 purchases and 6 sales selling 36,046 shares for an estimated $3,926,650.
- MICHAEL E. HURLSTON has made 0 purchases and 4 sales selling 2,500 shares for an estimated $228,906.
- BETHANY MAYER has made 0 purchases and 3 sales selling 686 shares for an estimated $60,003.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Astera Labs Hedge Fund Activity
We have seen 367 institutional investors add shares of Astera Labs stock to their portfolio, and 215 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ATREIDES MANAGEMENT, LP removed 3,697,481 shares (-79.5%) from their portfolio in Q2 2025, for an estimated $334,326,232
- VANGUARD GROUP INC added 2,751,747 shares (+29.6%) to their portfolio in Q2 2025, for an estimated $248,812,963
- BLACKROCK, INC. added 2,471,597 shares (+53.1%) to their portfolio in Q2 2025, for an estimated $223,481,800
- ALLIANCEBERNSTEIN L.P. removed 2,009,439 shares (-23.9%) from their portfolio in Q2 2025, for an estimated $181,693,474
- JENNISON ASSOCIATES LLC removed 1,736,440 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $103,613,374
- INVESCO LTD. removed 1,399,341 shares (-74.4%) from their portfolio in Q2 2025, for an estimated $126,528,413
- D. E. SHAW & CO., INC. removed 1,345,848 shares (-39.9%) from their portfolio in Q2 2025, for an estimated $121,691,576
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Astera Labs Analyst Ratings
Wall Street analysts have issued reports on $ALAB in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 08/07/2025
- Morgan Stanley issued a "Overweight" rating on 08/06/2025
- Stifel issued a "Buy" rating on 08/04/2025
- Jefferies issued a "Buy" rating on 07/22/2025
- William Blair issued a "Outperform" rating on 05/22/2025
- Evercore ISI Group issued a "Outperform" rating on 05/21/2025
- Needham issued a "Buy" rating on 05/07/2025
To track analyst ratings and price targets for Astera Labs, check out Quiver Quantitative's $ALAB forecast page.
Astera Labs Price Targets
Multiple analysts have issued price targets for $ALAB recently. We have seen 10 analysts offer price targets for $ALAB in the last 6 months, with a median target of $137.5.
Here are some recent targets:
- Tom O'Malley from Barclays set a target price of $155.0 on 08/07/2025
- Mehdi Hosseini from Susquehanna set a target price of $125.0 on 08/07/2025
- Joseph Moore from Morgan Stanley set a target price of $155.0 on 08/06/2025
- N. Quinn Bolton from Needham set a target price of $170.0 on 08/06/2025
- Mark Lipacis from Evercore ISI Group set a target price of $215.0 on 08/06/2025
- Tore Svanberg from Stifel set a target price of $145.0 on 08/04/2025
- Blayne Curtis from Jefferies set a target price of $130.0 on 07/22/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
